A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Non-alcoholic Steatohepatitis (NASH).
Latest Information Update: 27 Oct 2025
At a glance
- Drugs CS 060380 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Cascade Pharmaceuticals
Most Recent Events
- 21 Oct 2025 Status changed from not yet recruiting to recruiting.
- 06 Oct 2025 New trial record